![Response to IST and clonal evolution to MDS/AML in patients with AA with or without HLA− cells. (A) The distribution of the HLA− granulocyte percentages in AA patients with HLA− cells. Red bars indicate the median clone size. (B) The distribution of the GPI− granulocyte percentages in AA patients with GPI− cells. (C) The response to IST in AA patients with or without HLA− cells. *A significant difference P < .05. (D) The cumulative incidence of clonal evolution to MDS/AML in the overall population of patiens with AA. (E) The cumulative incidence of clonal evolution to MDS/AML in AA patients with (red line) or without (black line) HLA− cells. (F) The pie diagram indicates the proportions of concomitant aberrant clones detected in 127 patients with AA with HLA− cells. The bar graphs depict the number of patients with AA with HLA− cells and concomitant aberrant clones. (G) The pie diagrams indicates the proportions of HLA− cells and concomitant aberrant clones in 2 representative cases (unique patient number [UPN] 313 and UPN 631).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/137/25/10.1182_blood.2020010586/2/bloodbld2020010586f1.png?Expires=1743175747&Signature=OEFHn6Qi3qjxA2Ikvgzv8I3Il~0gH3Wfe7NLTJJn4R0MS0Wu5DCf3ZoDlJUTH-RZaH~xrt6EltVCl1TpFbH6r0UzSo5aU5QHczmRu~rVUpTWDSNYpPO0R3fExh4mreGUrwpiMP2KpUJlzwUUVOaEcSOYlUlvgXxcWDDP12pDg9bcf2TafxWFKX4ngJ2YEsTfJkFr93bb9ehgSTeNGI6DFfutQHfvHoJQwDCxT~IJYhFkvOL4lpfy8TinQRy4FWZXaHmv6RJwXTiisuYO7uPZh3VhfI6C7~d4HfvWB4B0iWd36e2PdCOxdp6uRCab39HJfbP58k06nw9i7SI8C-nqpg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Response to IST and clonal evolution to MDS/AML in patients with AA with or without HLA− cells. (A) The distribution of the HLA− granulocyte percentages in AA patients with HLA− cells. Red bars indicate the median clone size. (B) The distribution of the GPI− granulocyte percentages in AA patients with GPI− cells. (C) The response to IST in AA patients with or without HLA− cells. *A significant difference P < .05. (D) The cumulative incidence of clonal evolution to MDS/AML in the overall population of patiens with AA. (E) The cumulative incidence of clonal evolution to MDS/AML in AA patients with (red line) or without (black line) HLA− cells. (F) The pie diagram indicates the proportions of concomitant aberrant clones detected in 127 patients with AA with HLA− cells. The bar graphs depict the number of patients with AA with HLA− cells and concomitant aberrant clones. (G) The pie diagrams indicates the proportions of HLA− cells and concomitant aberrant clones in 2 representative cases (unique patient number [UPN] 313 and UPN 631).